Prothena Stock Price Target and Analyst Ratings (NASDAQ:PRTA)

Analyst Price Target for PRTA

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$28.29

▲ +26.73% Upside Potential

This price target is based on 7 analysts offering 12 month price targets for Prothena in the last 3 months. The average price target is $28.29, with a high forecast of $35.00 and a low forecast of $19.00. The average price target represents a 26.73% upside from the last price of $22.32.

Buy

The current consensus among 7 contributing investment analysts is to buy stock in Prothena. This rating has held steady since December 2019, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
2 buy ratings
0 hold ratings
1 sell ratings

Ratings as of

9/6/2019

0 strong buy ratings
2 buy ratings
0 hold ratings
1 sell ratings

Ratings as of

12/5/2019

0 strong buy ratings
3 buy ratings
0 hold ratings
1 sell ratings

Ratings as of

3/4/2020

0 strong buy ratings
4 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

6/2/2020

0 strong buy ratings
4 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

8/31/2020

0 strong buy ratings
5 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

11/29/2020

0 strong buy ratings
4 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

1/28/2021

0 strong buy ratings
7 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

2/27/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
2/26/2021	Royal Bank of Canada	Upgrade	Sector Perform ➝ Outperform	$14.00 ➝ $28.00	Medium	i
2/12/2021	Jefferies Financial Group	Upgrade	Hold ➝ Buy	$15.00 ➝ $30.00	Low	i
2/4/2021	HC Wainwright	Boost Price Target	Buy	$22.00 ➝ $33.00	Low	i Rating by A. Fein at HC Wainwright
2/2/2021	Oppenheimer	Boost Price Target	Outperform	$25.00 ➝ $35.00	Low	i
2/2/2021	BTIG Research	Upgrade	Neutral ➝ Buy	$29.00	Low	i
12/10/2020	Oppenheimer	Boost Price Target		$20.00 ➝ $25.00	Low	i Rating by Jay Olson at Oppenheimer Holdings Inc.
12/7/2020	HC Wainwright	Initiated Coverage	Buy	$22.00	Low	i Rating by A. Fein at HC Wainwright
10/21/2020	Cantor Fitzgerald	Boost Price Target	Positive ➝ Overweight	$20.00 ➝ $24.00	High	i
9/13/2020	Oppenheimer	Reiterated Rating	Buy	$18.00	High	i Rating by Jay Olson at Oppenheimer Holdings Inc.
7/8/2020	Oppenheimer	Upgrade	Market Perform ➝ Outperform	$16.00	High	i Rating by Jay Olson at Oppenheimer Holdings Inc.
5/13/2020	Oppenheimer	Reiterated Rating	Hold		High	i Rating by Jay Olson at Oppenheimer Holdings Inc.
5/10/2020	Nomura	Reiterated Rating	Buy	$19.00	High	i
4/23/2020	Oppenheimer	Reiterated Rating	Hold		Low	i
1/1/2020	Nomura Securities	Reiterated Rating	Buy	$19.00	Low	i
12/22/2019	Evercore ISI	Reiterated Rating	Buy	$14.00	High	i
11/27/2019	Evercore ISI	Upgrade	In-Line ➝ Outperform		Low	i
11/19/2019	Evercore ISI	Upgrade	In-Line ➝ Outperform	$14.00	High	i
5/31/2019	Barclays	Reiterated Rating	Sell	$9.00	Low	i
5/16/2019	Cantor Fitzgerald	Reiterated Rating	Overweight		High	i Rating by C. Duncan at Cantor Fitzgerald
3/4/2019	Cantor Fitzgerald	Initiated Coverage	Overweight	$13.77	High	i Rating by M. Lillis at Cantor Fitzgerald
11/23/2018	Cantor Fitzgerald	Reiterated Rating	Overweight		High	i Rating by M. Lillis at Cantor Fitzgerald
11/11/2018	Oppenheimer	Reiterated Rating	Hold		High	i Rating by Jay Olson at Oppenheimer Holdings Inc.
8/8/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$18.00	Low	i Rating by William Tanner at Cantor Fitzgerald
6/15/2018	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Buy	$14.00 ➝ $18.00	High	i
5/25/2018	Oppenheimer	Reiterated Rating	Hold		Low	i Rating by Jay Olson at Oppenheimer Holdings Inc.
5/21/2018	Barclays	Downgrade	Equal Weight ➝ Underweight	$12.00	High	i Rating by Geoff Meacham at Barclays PLC
5/9/2018	Oppenheimer	Reiterated Rating	Hold		High	i Rating by Jay Olson at Oppenheimer Holdings Inc.
4/24/2018	Nomura Securities	Lower Price Target	Buy ➝ Buy	$87.00 ➝ $19.00	High	i
4/24/2018	Wedbush	Lower Price Target	Neutral	$46.00 ➝ $13.00	High	i Rating by D. Nierengarten at Wedbush
4/24/2018	BTIG Research	Downgrade	Buy ➝ Neutral	$77.00	High	i
4/24/2018	Deutsche Bank Aktiengesellschaft	Reiterated Rating	Buy ➝ Buy	$78.00 ➝ $16.00	High	i Rating by Andrew Peters at Deutsche Bank Aktiengesellschaft
4/24/2018	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$69.00 ➝ $14.00	High	i
4/23/2018	Oppenheimer	Downgrade	Outperform ➝ Hold		High	i Rating by Jay Olson at Oppenheimer Holdings Inc.
4/23/2018	Royal Bank of Canada	Downgrade	Outperform ➝ Sector Perform	$87.00	High	i
4/23/2018	Barclays	Downgrade	Overweight ➝ Equal Weight		High	i
4/23/2018	Jefferies Financial Group	Downgrade	Buy ➝ Hold		High	i
4/5/2018	Barclays	Lower Price Target	Overweight ➝ Overweight	$70.00 ➝ $50.00	Medium	i
3/21/2018	Deutsche Bank Aktiengesellschaft	Reiterated Rating	Buy		High	i Rating by Andrew Peters at Deutsche Bank Aktiengesellschaft
3/21/2018	Cantor Fitzgerald	Reiterated Rating	Overweight	$69.00	High	i
3/21/2018	Oppenheimer	Set Price Target	Buy	$70.00	High	i Rating by Jay Olson at Oppenheimer Holdings Inc.
2/15/2018	Oppenheimer	Set Price Target	Buy	$70.00	High	i Rating by Jay Olson at Oppenheimer Holdings Inc.
2/4/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$65.00	High	i
12/20/2017	Cantor Fitzgerald	Reiterated Rating	Buy	$65.00	Medium	i
12/4/2017	Oppenheimer	Set Price Target	Buy	$70.00	High	i Rating by Jay Olson at Oppenheimer Holdings Inc.
11/20/2017	Wedbush	Downgrade	Outperform ➝ Neutral	$75.00 ➝ $55.00	N/A	i Rating by D. Nierengarten at Wedbush
11/9/2017	Oppenheimer	Reiterated Rating	Buy	$70.00	N/A	i
10/23/2017	Deutsche Bank Aktiengesellschaft	Set Price Target	Buy	$73.00	N/A	i Rating by Andrew Peters at Deutsche Bank Aktiengesellschaft
10/2/2017	Jefferies Financial Group	Reiterated Rating	Buy	$100.00	Low	i
10/2/2017	SunTrust Banks	Reiterated Rating	Buy	$75.00	Low	i
10/1/2017	Deutsche Bank Aktiengesellschaft	Reiterated Rating	Buy		Low	i Rating by Andrew Peters at Deutsche Bank Aktiengesellschaft
9/29/2017	Royal Bank of Canada	Reiterated Rating	Buy		High	i
9/29/2017	BTIG Research	Lower Price Target	Buy ➝ Buy	$80.00 ➝ $77.00	High	i Rating by Robert Hazlett at BTIG Research
9/28/2017	Cantor Fitzgerald	Reiterated Rating	Buy	$79.00	Medium	i
9/14/2017	Royal Bank of Canada	Initiated Coverage	Outperform ➝ Outperform	$87.00	High	i
8/16/2017	Evercore ISI	Initiated Coverage	Outperform ➝ Outperform	$83.00	High	i
7/10/2017	Jefferies Financial Group	Initiated Coverage	Buy ➝ Buy	$100.00	Medium	i
7/6/2017	Oppenheimer	Reiterated Rating	Outperform	$70.00	Low	i Rating by Jay Olson at Oppenheimer Holdings Inc.
5/19/2017	BTIG Research	Initiated Coverage	Buy	$80.00	High	i
5/16/2017	Piper Jaffray Companies	Reiterated Rating	Buy		Medium	i Rating by Steven Breazzano at Piper Jaffray Companies
5/11/2017	Oppenheimer	Set Price Target	Buy	$70.00	Low	i Rating by Jay Olson at Oppenheimer Holdings Inc.
4/12/2017	Cantor Fitzgerald	Initiated Coverage	Overweight	$86.00	High	i
4/12/2017	Piper Jaffray Companies	Initiated Coverage	Overweight ➝ Overweight	$69.00	Medium	i
4/6/2017	Oppenheimer	Set Price Target	Buy	$70.00	Low	i Rating by Jay Olson at Oppenheimer Holdings Inc.
4/3/2017	Wedbush	Reiterated Rating	Outperform	$77.00	High	i Rating by D. Nierengarten at Wedbush
3/22/2017	Oppenheimer	Reiterated Rating	Buy		Low	i Rating by Jay Olson at Oppenheimer Holdings Inc.
3/1/2017	Nomura Instinet	Initiated Coverage	Buy ➝ Buy	$87.00	N/A	i
3/1/2017	Nomura Securities	Initiated Coverage	Buy		N/A	i
2/15/2017	Wedbush	Reiterated Rating	Outperform	$77.00	N/A	i Rating by D. Nierengarten at Wedbush
12/20/2016	SunTrust Banks	Initiated Coverage	Buy	$75.00	N/A	i
12/6/2016	Wedbush	Reiterated Rating	Outperform	$77.00	N/A	i
11/10/2016	Wedbush	Reiterated Rating	Outperform	$77.00	N/A	i
11/3/2016	Deutsche Bank Aktiengesellschaft	Initiated Coverage	Buy	$73.00	N/A	i
10/31/2016	Wedbush	Reiterated Rating	Outperform	$77.00	N/A	i
9/27/2016	Credit Suisse Group	Reiterated Rating	Buy	$65.00	N/A	i Rating by Kennen MacKay at Credit Suisse Group AG
9/26/2016	Wedbush	Reiterated Rating	Outperform	$77.00	N/A	i
9/11/2016	Credit Suisse Group	Reiterated Rating	Buy	$65.00	N/A	i Rating by Kennen MacKay at Credit Suisse Group AG
8/4/2016	Barclays	Boost Price Target	Overweight	$60.00 ➝ $70.00	N/A	i Rating by Geoff Meacham at Barclays PLC
8/4/2016	UBS Group	Reiterated Rating	Buy	$73.00	N/A	i Rating by Jeffrey Hung at UBS Group AG
8/3/2016	Wedbush	Reiterated Rating	Outperform	$77.00	N/A	i
7/18/2016	Royal Bank of Canada	Reiterated Rating	Outperform	$95.00	N/A	i Rating by Michael Yee at Royal Bank of Canada
7/12/2016	Credit Suisse Group	Reiterated Rating	Buy		N/A	i Rating by Kennen MacKay at Credit Suisse Group AG
7/5/2016	Wedbush	Reiterated Rating	Outperform	$77.00	N/A	i
6/22/2016	Royal Bank of Canada	Reiterated Rating	Buy		N/A	i Rating by Michael Yee at Royal Bank of Canada
6/10/2016	Royal Bank of Canada	Reiterated Rating	Buy		N/A	i Rating by Michael Yee at Royal Bank of Canada
6/10/2016	Credit Suisse Group	Reiterated Rating	Buy		N/A	i Rating by Kennen MacKay at Credit Suisse Group AG
6/10/2016	UBS Group	Reiterated Rating	Buy	$73.00	N/A	i
5/13/2016	Barclays	Initiated Coverage	Overweight	$60.00	N/A	i
5/4/2016	Credit Suisse Group	Reiterated Rating	Buy		N/A	i Rating by Kennen MacKay at Credit Suisse Group AG
3/15/2016	Oppenheimer	Reiterated Rating	Outperform	$77.00	N/A	i Rating by Christopher Marai at Oppenheimer Holdings Inc.

(Data available from 2/27/2016 forward)

Prothena Corporation plc, a clinical-stage neuroscience company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, an antibody that is in Phase I clinical trial for the treatment of ATTR amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, progressive supranuclear palsy, frontotemporal dementia, chronic traumatic encephalopathy, and other tauopathies; AÃ, or Amyloid Beta, a protein for the treatment of Alzheimer's disease; TDP-43 for amyotrophic lateral sclerosis and frontotemporal dementia; and other products for neurodegeneration. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. Prothena Corporation plc was founded in 2012 and is based in Dublin, Ireland.

Today's Range

Now: $22.32

$22.26

$24.74

50 Day Range

MA: $16.15

$11.00

$24.00

52 Week Range

Now: $22.32

$7.10

$27.20

Volume

447,776 shs

Average Volume

468,350 shs

Market Capitalization

$891.04 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.71

Frequently Asked Questions

What sell-side analysts currently cover shares of Prothena?

The following sell-side analysts have issued stock ratings on Prothena in the last twelve months: BTIG Research, Cantor Fitzgerald, HC Wainwright, Jefferies Financial Group Inc., Nomura, Oppenheimer Holdings Inc., Royal Bank of Canada, and Zacks Investment Research.
View the latest analyst ratings for PRTA.

What is the current price target for Prothena?

7 Wall Street analysts have set twelve-month price targets for Prothena in the last year. Their average twelve-month price target is $28.29, suggesting a possible upside of 26.7%. Oppenheimer Holdings Inc. has the highest price target set, predicting PRTA will reach $35.00 in the next twelve months. Nomura has the lowest price target set, forecasting a price of $19.00 for Prothena in the next year.
View the latest price targets for PRTA.

What is the current consensus analyst rating for Prothena?

Prothena currently has 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PRTA will outperform the market and that investors should add to their positions of Prothena.
View the latest ratings for PRTA.

What other companies compete with Prothena?

Other companies that are similar to Prothena include Karuna Therapeutics, Agios Pharmaceuticals, MorphoSys, Amicus Therapeutics, Pacira BioSciences, Rocket Pharmaceuticals, Alkermes, OPKO Health, ALX Oncology, Corcept Therapeutics, Viela Bio, Intra-Cellular Therapies, Xencor, Taro Pharmaceutical Industries and Prelude Therapeutics.

How do I contact Prothena's investor relations team?

Prothena's physical mailing address is 77 SIR JOHN ROGERSON`S QUAY BLOCK C GRAND CANAL DOCKLANDS, DUBLIN 2 L2, D02 T804. The biotechnology company's listed phone number is 011-353-1236-2500 and its investor relations email address is [email protected] The official website for Prothena is www.prothena.com.

NASDAQ:PRTA - Prothena Stock Price Target and Predictions

Analyst Price Target for PRTA

Past Monthly Recommendations

Latest Recommendations

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Prothena?

What is the current price target for Prothena?

What is the current consensus analyst rating for Prothena?

What other companies compete with Prothena?

How do I contact Prothena's investor relations team?